Chai Discovery vs Epic Systems
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI molecular discovery unicorn ($1.3B valuation). 100x improvement in de novo antibody design success. Backed by OpenAI. Eli Lilly partnership. Founded 2023, SF. $225M+ raised.
About
Chai Discovery is an AI-driven molecular discovery company founded in 2024 and headquartered in San Francisco. The company was spun out of research conducted by scientists with backgrounds at leading computational biology and AI organizations, with the founding mission of applying the latest advances in generative AI to accelerate drug discovery — particularly the historically difficult challenge of designing novel antibodies and small molecules from scratch rather than optimizing known chemical scaffolds.\n\nChai's core technology is a foundation model for molecular structure prediction and de novo design that operates across proteins, small molecules, nucleic acids, and their complexes. The company's flagship research achievement is a reported 100-fold improvement in de novo antibody design success rates, enabling the generation of functional antibody candidates without requiring extensive experimental screening campaigns. Chai Discovery has established a research partnership with Eli Lilly, one of the world's largest pharmaceutical companies, to apply its platform to therapeutic target programs. The company is backed by OpenAI, reflecting the deep connection between large-scale AI modeling techniques and the biological sequence-structure-function prediction task.\n\nChai Discovery reached a $1.3 billion valuation within its first year of operation, an exceptionally rapid ascent reflecting the strategic premium investors place on AI-native molecular discovery platforms. The company operates at the intersection of structural biology, generative AI, and therapeutic development, competing with platforms like Isomorphic Labs, Recursion, and Insilico Medicine in the race to demonstrate AI-designed drugs in human clinical trials.
Epic holds over 42% of U.S. acute care hospital EHR market share and is embedding AI across 150+ clinical workflows for 2026, while facing antitrust scrutiny.
About
Epic Systems Corporation was founded in 1979 by Judith Faulkner and is headquartered in Verona, Wisconsin, remaining privately held with Faulkner as majority owner. The company develops large-scale electronic health record systems and reports that more than 305 million patients have a record in Epic, covering the majority of U.S. academic medical centers and large health systems including Kaiser Permanente, Mayo Clinic, Johns Hopkins, and Cleveland Clinic. Epic commands approximately 42% of U.S. acute care hospitals and nearly 55% of acute care hospital beds, making it the undisputed market leader in enterprise EHR.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.